Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > tacrolimus market
Get a free sample of Tacrolimus Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Tacrolimus Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The tacrolimus industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different formulations is among a key market strategy. Some of the leading industry players including Abbott Laboratories, Astellas Pharma Inc., Novartis AG, Biocon Ltd., and Glenmark Pharmaceuticals Ltd. among others have a notable presence in the market.
Some of the eminent market participants operating in the tacrolimus industry include:
The injections segment is estimated to account for USD 4.1 billion in revenue by 2032, owing to their increasing use in the critical post-operative period to ensure timely and effective immunosuppression, particularly in patients that are unable to tolerate oral medications.
North America market size was valued at USD 2.7 billion in 2023, owing to the presence of advanced healthcare infrastructure, including specialized transplant centers, hospitals, and clinics equipped to perform organ transplant surgeries.
Some of the top companies engaged in the industry are Abbott Laboratories, Astellas Pharma Inc., Biocon Ltd., F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd., GSK plc, Lupin Pharmaceuticals Ltd, Novartis, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc.
The market size of tacrolimus reached USD 6.6 billion in revenue in 2023 and is set to witness 5.6% CAGR from 2024 to 2032, led by the rising number of organ transplant procedures and the increasing prevalence of autoimmune diseases.